Compounders Research Compare

Kura Oncology, Inc.(KURA)

Biotechnology · San Diego, CA

$10.53-0.09 (-0.85%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

San Diego, CA

260 employees

kuraoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Troy Wilson

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T21:37:25.427Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:37:25.427Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 934,794,063
Total debt · period ending 2026-06-30: 24,455,000
Cash · period ending 2026-06-30: 70,242,000
TTM operating income · period ending 2026-06-30: -318,090,000

FMP input reference: 19f1946388931e4ee5326c5171249fc23a65b0c9e42408d49e268755c1a57655

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KURA EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

KURA Competitors' EV/EBIT Ratio

Kura Oncology, Inc.

Current

Market Cap

$934.79M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Seaport Therapeutics, Inc. Common Stock

Market Cap

$929.83M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CeriBell, Inc.

Market Cap

$923.53M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MoonLake Immunotherapeutics

Market Cap

$921.06M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Savara Inc.

Market Cap

$952.91M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aktis Oncology, Inc.

Market Cap

$953.81M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HealthStream, Inc.

Market Cap

$914.73M

EV/EBIT Ratio

34.18x

TTM Avg

30.80x

3Y Avg

40.41x

5Y Avg

53.37x

Pacira BioSciences, Inc.

Market Cap

$973.93M

EV/EBIT Ratio

63.98x

TTM Avg

51.40x

3Y Avg

38.19x

5Y Avg

39.85x

Latigo Biotherapeutics Inc.

Market Cap

$978.09M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Corvus Pharmaceuticals, Inc.

Market Cap

$887.99M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Kura Oncology, Inc. (KURA)	$934.79M	N/A	N/A	N/A	N/A
Seaport Therapeutics, Inc. Common Stock (SPTX)vs ›	$929.83M	N/A	N/A	N/A	N/A
CeriBell, Inc. (CBLL)vs ›	$923.53M	N/A	N/A	N/A	N/A
MoonLake Immunotherapeutics (MLTX)vs ›	$921.06M	N/A	N/A	N/A	N/A
Savara Inc. (SVRA)vs ›	$952.91M	N/A	N/A	N/A	N/A
Aktis Oncology, Inc. (AKTS)vs ›	$953.81M	N/A	N/A	N/A	N/A
HealthStream, Inc. (HSTM)vs ›	$914.73M	34.18x	30.80x	40.41x	53.37x
Pacira BioSciences, Inc. (PCRX)vs ›	$973.93M	63.98x	51.40x	38.19x	39.85x
Latigo Biotherapeutics Inc. (LTGO)vs ›	$978.09M	N/A	N/A	N/A	N/A
Corvus Pharmaceuticals, Inc. (CRVS)vs ›	$887.99M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics